While pharmacy and therapeutics (P&T) committees have had significant influence in drug coverage decisions for decades, their workings remain mostly shrouded in secrecy, Reuters reports.
According to the report, experts on those committees recently suggested that three new drugs aimed at preventing migraines offered no clear benefit over existing drugs in the market. The drugs, which were described as “breakthrough” treatments by their respective manufacturer, each carried a roughly $7,000 price tag.
Using the committee’s recommendations, OptumRx proceeded to demand significant discounts on the drugs.
To read the full report on Reuters, click here.
